Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANESH A ALAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1043227200
CMS profile
1133215
Location
WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$17,495.83

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,730.00 3
Travel and Lodging $1,878.16 6
Food and Beverage $887.67 15

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $7,500.00 1
US WorldMeds, LLC $5,144.56 11
Janssen Pharmaceuticals, Inc $4,351.45 8
LivaNova USA, Inc. $499.82 4

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANESH A ALAM

NPI 1043227200 · CMS profile ID 1133215

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

WINFIELD, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DANESH A ALAM, NPI 1043227200, CMS profile ID 1133215, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1043227200?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $17,495.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $315.8109/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470275 CMS
LivaNova USA, Inc. $55.0109/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470269 CMS
LivaNova USA, Inc. $60.0009/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470271 CMS
LivaNova USA, Inc. $69.0009/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703470273 CMS
Janssen Pharmaceuticals, Inc $3,030.0009/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258027 CMS
Janssen Pharmaceuticals, Inc $1,161.2309/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258029 CMS
Janssen Pharmaceuticals, Inc $12.9309/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258031 CMS
Janssen Pharmaceuticals, Inc $43.1009/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258033 CMS
Janssen Pharmaceuticals, Inc $12.9309/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258035 CMS
Janssen Pharmaceuticals, Inc $29.4309/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258037 CMS
Janssen Pharmaceuticals, Inc $26.9209/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258039 CMS
Janssen Pharmaceuticals, Inc $34.9109/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658258041 CMS
US WorldMeds, LLC $125.9308/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499741 CMS
US WorldMeds, LLC $109.6808/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499743 CMS
US WorldMeds, LLC $38.0508/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499745 CMS
US WorldMeds, LLC $115.4808/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499747 CMS
US WorldMeds, LLC $7.3508/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499749 CMS
US WorldMeds, LLC $289.0008/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499751 CMS
US WorldMeds, LLC $50.2908/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499753 CMS
US WorldMeds, LLC $61.2108/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499755 CMS
US WorldMeds, LLC $18.9708/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499757 CMS
US WorldMeds, LLC $4,200.0008/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499609 CMS
US WorldMeds, LLC $128.6008/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699499611 CMS
Alkermes, Inc. $7,500.0002/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686569833 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,495.83 24
PY2020 $2,250.00 4
PY2024 $1,068.69 8
PY2025 $16,767.00 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,292.36 12
PY2025 Principal investigator $131,175.91 17
PY2024 Principal investigator $333,688.72 94
PY2023 Principal investigator $642,167.72 100
PY2022 Principal investigator $346,465.71 57
PY2021 Principal investigator $149,586.53 50
PY2020 Principal investigator $478,016.95 67
PY2019 Recipient $1,282.88 8
PY2019 Principal investigator $534,507.18 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $141.72 12/31/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features No dispute reported 06/30/2026 998414681
Principal investigator 1 Indivior Inc. $2,644.00 12/19/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845929
Principal investigator 1 Janssen Research & Development, LLC $6,552.00 12/18/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159097
Principal investigator 1 Indivior Inc. $5,134.00 12/12/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845713
Principal investigator 1 Indivior Inc. $1,860.00 12/08/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845637
Principal investigator 1 Indivior Inc. $3,434.00 11/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845499
Principal investigator 1 Indivior Inc. $505.38 11/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845523
Principal investigator 1 Indivior Inc. $4,896.00 11/21/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845269
Principal investigator 1 Indivior Inc. $5,075.00 11/17/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845173
Principal investigator 1 ITI, Inc. $15.00 11/13/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042730201
Principal investigator 1 Indivior Inc. $4,829.00 11/07/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038845061
Principal investigator 1 Indivior Inc. $1,109.00 11/02/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844951
Principal investigator 1 Janssen Research & Development, LLC $9,483.00 11/02/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159095
Principal investigator 1 Indivior Inc. $10,657.00 10/25/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844701
Principal investigator 1 Indivior Inc. $2,431.00 10/17/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844487
Principal investigator 1 Indivior Inc. $1,022.36 10/10/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844347
Principal investigator 1 Indivior Inc. $6,473.00 10/10/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844399
Principal investigator 1 Indivior Inc. $15,050.00 10/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844159
Principal investigator 1 Indivior Inc. $7,541.00 10/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844165
Principal investigator 1 Indivior Inc. $1,941.00 10/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038844171
Principal investigator 1 Janssen Research & Development, LLC $4,301.00 10/02/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159093
Principal investigator 1 ITI, Inc. $4,382.15 09/29/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042725671
Principal investigator 1 ITI, Inc. $882.24 09/29/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042725697
Principal investigator 1 Indivior Inc. $19,251.00 09/21/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843953
Principal investigator 1 Indivior Inc. $12,069.00 09/12/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843801
Principal investigator 1 Indivior Inc. $432.75 09/12/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843807
Principal investigator 1 Indivior Inc. $6,016.00 09/06/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843613
Principal investigator 1 Indivior Inc. $23,957.00 09/01/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843425
Principal investigator 1 Janssen Research & Development, LLC $5,337.00 08/31/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159091
Principal investigator 1 ITI, Inc. $9,943.73 08/25/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042724381
Principal investigator 1 Indivior Inc. $18,638.00 08/23/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843281
Principal investigator 1 Indivior Inc. $2,252.00 08/18/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843147
Principal investigator 1 Indivior Inc. $10,682.00 08/10/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038843017
Principal investigator 1 Janssen Research & Development, LLC $7,839.00 07/31/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159087
Principal investigator 1 ITI, Inc. $3,215.59 07/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042723019
Principal investigator 1 ITI, Inc. $1,336.29 07/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042723045
Principal investigator 1 Indivior Inc. $20,216.00 07/26/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038842521
Principal investigator 1 Indivior Inc. $1,537.02 07/26/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038842527
Principal investigator 1 Indivior Inc. $774.31 07/18/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038842145
Principal investigator 1 Indivior Inc. $6,935.00 07/18/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038842157
Principal investigator 1 Indivior Inc. $1,182.00 07/11/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038842007
Principal investigator 1 Indivior Inc. $3,753.00 07/04/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841891
Principal investigator 1 Janssen Research & Development, LLC $30,651.00 07/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159089
Principal investigator 1 ITI, Inc. $2,667.18 06/30/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042721635
Principal investigator 1 Indivior Inc. $4,291.00 06/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841737
Principal investigator 1 Indivior Inc. $771.99 06/27/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841681
Principal investigator 1 Indivior Inc. $3,882.00 06/20/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841549
Principal investigator 1 Indivior Inc. $8,083.00 06/13/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841427
Principal investigator 1 Indivior Inc. $6,288.00 06/08/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841289
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $4,569.50 06/01/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1014044453
Principal investigator 1 Indivior Inc. $4,509.00 05/30/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841119
Principal investigator 1 Janssen Research & Development, LLC $1,640.00 05/29/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159083
Principal investigator 1 ITI, Inc. $7,022.86 05/26/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042720095
Principal investigator 1 Indivior Inc. $6,800.00 05/24/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038841025
Principal investigator 1 Indivior Inc. $4,496.00 05/16/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840863
Principal investigator 1 Indivior Inc. $856.22 05/10/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840793
Principal investigator 1 Indivior Inc. $14,269.00 05/09/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840743
Principal investigator 1 Indivior Inc. $1,427.00 05/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840567
Principal investigator 1 Indivior Inc. $5,316.00 05/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840573
Principal investigator 1 Janssen Research & Development, LLC $17,329.00 05/01/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159085
Principal investigator 1 ITI, Inc. $2,783.60 04/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042718623
Principal investigator 1 ITI, Inc. $8,886.12 04/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042718651
Principal investigator 1 Indivior Inc. $8,989.00 04/26/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840337
Principal investigator 1 Indivior Inc. $2,252.00 04/26/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840343
Principal investigator 1 Indivior Inc. $15,628.00 04/18/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840127
Principal investigator 1 Indivior Inc. $8,366.00 04/13/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839915
Principal investigator 1 Indivior Inc. $942.77 04/13/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038840003
Principal investigator 1 Indivior Inc. $1,322.00 04/04/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839689
Principal investigator 1 Indivior Inc. $8,930.00 04/04/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839693
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $16,705.30 04/04/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1014042985
Principal investigator 1 Indivior Inc. $12,796.00 03/29/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839563
Principal investigator 1 ITI, Inc. $180.00 03/24/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042717629
Principal investigator 1 ITI, Inc. $7,131.83 03/24/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042717659
Principal investigator 1 Janssen Research & Development, LLC $9,246.00 03/24/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159075
Principal investigator 1 Indivior Inc. $3,400.00 03/21/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839371
Principal investigator 1 Indivior Inc. $5,923.00 03/21/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839377
Principal investigator 1 Indivior Inc. $858.54 03/20/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839321
Principal investigator 1 Indivior Inc. $15,379.00 03/15/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839229
Principal investigator 1 Indivior Inc. $1,630.00 03/08/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038839115
Principal investigator 1 Indivior Inc. $8,576.00 02/28/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838905
Principal investigator 1 Janssen Research & Development, LLC $12,069.00 02/27/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159079
Principal investigator 1 ITI, Inc. $17,059.68 02/24/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042716665
Principal investigator 1 Indivior Inc. $7,386.00 02/22/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838699
Principal investigator 1 Indivior Inc. $2,364.00 02/22/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838707
Principal investigator 1 Indivior Inc. $603.53 02/22/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838831
Principal investigator 1 Indivior Inc. $3,819.00 02/16/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838535
Principal investigator 1 Indivior Inc. $1,684.00 02/09/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838365
Principal investigator 1 ITI, Inc. $75.00 02/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042716109
Principal investigator 1 ITI, Inc. $120.00 02/03/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042716123
Principal investigator 1 Indivior Inc. $13,702.00 02/02/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838229
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,483.91 02/01/2023 Non-covered Recipient Entity
NEUROPSYCH CENTER OF PALM BEACHES
A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent No dispute reported 06/30/2026 1017210217
Principal investigator 1 Janssen Research & Development, LLC $516.00 01/30/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159077
Principal investigator 1 ITI, Inc. $14,082.94 01/27/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042715475
Principal investigator 1 ITI, Inc. $7,534.46 01/27/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE INC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042715503
Principal investigator 1 Janssen Research & Development, LLC $27,888.00 01/27/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE OF FLORIDA LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 986159081
Principal investigator 1 Indivior Inc. $432.75 01/23/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTEAMBROSIA
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038838057
Principal investigator 1 Indivior Inc. $4,246.00 01/20/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038837939
Principal investigator 1 Indivior Inc. $1,280.00 01/10/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038837799
Principal investigator 1 Indivior Inc. $3,235.00 01/06/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038837605
Principal investigator 1 Indivior Inc. $1,067.00 01/06/2023 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH INSTITUTE
A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use No dispute reported 06/30/2026 1038837611